The stock will trade on SANRECO Phase 2 readout in August 2026, not Q1 financials. Monitor abstract presentations at EHA (June) and EAS (May) for additional pipeline signals.
Price Chart
Executive Summary
Silence Therapeutics reported Q1 2026 revenue of $0.4M vs consensus $1.5M, a significant miss reflecting early-stage biotech volatility. Net loss narrowed to $15.0M ($0.11 per share) from $28.5M YoY, driven by lower R&D spend. The key catalyst remains Phase 2 SANRECO topline in August 2026.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $0.4M; consensus was $1.5M (miss)
- Net loss $15.0M vs $28.5M YoY, improvement due to lower R&D expenses
- Cash & investments $70.1M as of March 31, 2026
- Phase 2 SANRECO trial (divesiran) on track for topline results in August 2026
- SLN312 Phase 1 abstract accepted for late-breaking oral at EAS Congress
Financial Impact
Revenue miss of $1.1M (73% below consensus) but pre-revenue biotech; cash burn manageable
Risk Factors
- Phase 2 SANRECO trial failure or delay
- Cash runway only ~12 quarters at current burn rate without additional partnering or financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210428 |
| Document: sln-20260507.htm | 0001193125-26-210428 |
| Document: 0001193125-26-210428-index-headers.html | 0001193125-26-210428 |
| Document: 0001193125-26-210428-index.html | 0001193125-26-210428 |
| Document: 0001193125-26-210428.txt | 0001193125-26-210428 |
| 8-K Data (Synthetic) | 0001193125-26-210428 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 28, 2026 21w ago | EFFECT | $1.06 $1.06 | · 0.00% | ▲ +0.33% | $6.37 (−500.94%) |
May 27, 2026 21w ago | 424B5 | $1.06 $1.06 | · 0.00% | ▲ +0.33% | $6.37 (−500.94%) |
May 18, 2026 23w ago | S-3 | $1.45 $1.06 | ▲ +27.02% | ▲ +29.32% | $6.37 (−338.55%) |
May 7, 2026 24w ago | 8-K | $2.63 $1.45 | ▼ −44.77% | ▼ −46.28% | $6.37 (+142.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers